What it's for (Indications)
- This combination vaccine is indicated for active immunization against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and invasive diseases caused by Haemophilus influenzae type b (Hib) in infants and young children.
- It is primarily used for the initial primary immunization series, typically administered during infancy, to establish robust protective immunity against these five serious infectious diseases.
- The vaccine helps prevent severe complications associated with these pathogens, such as respiratory obstruction in diphtheria, muscle spasms and lockjaw in tetanus, severe coughing fits and apnea in pertussis, chronic liver disease and liver cancer from hepatitis B, and meningitis, epiglottis, or sepsis caused by Hib.
- Adherence to recommended immunization schedules is crucial for optimal protection and public health, contributing significantly to the reduction of disease burden in pediatric populations and preventing outbreaks.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The standard dosage for this combination vaccine is a single 0.5 mL dose administered intramuscularly. The primary immunization series typically consists of three doses given during the first year of life, commencing at 6 weeks of age, with subsequent doses administered at intervals of at least 4 weeks. For example, a common schedule might be at 2, 4, and 6 months of age, in accordance with national immunization program guidelines. The exact dosing schedule may vary based on local public health recommendations and specific product labeling. It is crucial to ensure that the vaccine is administered deeply into the anterolateral aspect of the thigh in infants and young children to minimize local reactions and ensure optimal immunogenicity. Care should be taken to avoid intravascular injection, which could lead to severe systemic reactions. Any deviations from the recommended schedule should be promptly addressed with a healthcare provider to ensure catch-up immunization is completed effectively. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse reactions following administration of this vaccine are generally mild to moderate and transient.
- These include local injection site reactions such as pain, tenderness, redness (erythema), and swelling (induration or edema), which typically resolve within 24-48 hours.
- Systemic reactions may include fever (oral temperature ≥38°C), irritability, fussiness, drowsiness, somnolence, loss of appetite, and occasional gastrointestinal disturbances like vomiting or diarrhea.
- Less common but more severe reactions can include persistent, inconsolable crying lasting for several hours, hypotonic-hyporesponsive episodes (HHE), and febrile seizures.
- Serious adverse events, such as anaphylaxis, are exceedingly rare but constitute medical emergencies requiring immediate intervention.
- Allergic reactions, including generalized rash and urticaria, may also occur.
- Healthcare providers should counsel parents/guardians about potential side effects, provide instructions for managing mild reactions, and advise on symptoms that warrant immediate medical attention.
Serious Warnings
- Black Box Warning: This specific DTaP-HepB-Hib combination vaccine *does not* carry a formal FDA Black Box Warning. However, it is imperative for healthcare providers to be aware of several serious safety considerations. **Serious Warnings:** While rare, severe allergic reactions (anaphylaxis) can occur and require immediate medical intervention with epinephrine. Healthcare facilities administering vaccines must have appropriate medical treatment and supervision immediately available to manage such events. Additionally, encephalopathy not attributable to another cause occurring within 7 days of a previous pertussis-containing vaccination is a contraindication for further pertussis vaccination. There is an increased risk of apnea and the need for respiratory monitoring in very premature infants (born ≤ 28 weeks of gestation) following primary immunization, especially in the first 72 hours post-vaccination. Providers must ensure the vaccine is administered strictly intramuscularly and never intravenously, as intravascular injection can lead to severe systemic reactions. Patients should be monitored for syncope (fainting) after vaccination to prevent injury from falls.
- This vaccine should be administered with caution to individuals with a history of severe systemic reactions to previous doses or known hypersensitivity to any vaccine component.
- Administration should be postponed in persons suffering from acute severe febrile illness; however, minor infections with or without low-grade fever are generally not contraindications.
- For infants born prematurely, especially those with a history of respiratory immaturity (e.
- g.
- , ≤ 28 weeks of gestation), there is a potential for apnea following intramuscular vaccination; therefore, respiratory monitoring for 48-72 hours may be considered for this high-risk group.
- The vaccine must not be administered intravenously under any circumstances, as intravascular injection can lead to severe systemic reactions and reduced efficacy.
- Individuals with thrombocytopenia or any bleeding disorder should be vaccinated with caution, with appropriate measures taken to minimize the risk of bleeding or bruising following intramuscular injection.
- Syncope (fainting) can occur following or even before vaccination, and procedures should be in place to prevent injury from falls.
How it Works (Mechanism of Action)
This vaccine induces active immunity by introducing purified antigens from diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b to the immune system. Diphtheria toxoid and tetanus toxoid are inactivated bacterial toxins (toxoids) that stimulate the production of antitoxin antibodies, effectively neutralizing the harmful effects of the bacteria without causing disease. The acellular pertussis components (pertussis toxoid, filamentous hemagglutinin, pertactin) are purified bacterial proteins that induce both humoral (antibody-mediated) and cellular immune responses against Bordetella pertussis. The HBsAg protein (Hepatitis B surface antigen) from Hepatitis B virus elicits protective antibodies against the virus, preventing infection. The Haemophilus influenzae type b component is a polysaccharide conjugated to a protein carrier, which enhances immunogenicity in infants, leading to the production of bactericidal antibodies. These specific antibodies and cell-mediated immune responses provide long-term protection against the respective pathogens upon subsequent exposure, preventing disease development and reducing the severity of illness.
Commercial Brands (Alternatives)
No other brands found for this formula.